Your session is about to expire
← Back to Search
18F-Fluciclovine for Cervical Cancer
Phase 4
Waitlist Available
Led By Bital Savir-Baruch, M.D
Research Sponsored by Bital Savir-Baruch
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
GYN cancer (ovarian, endometrial, or cervical) was biopsy-proven and/or schedule for subsequent surgery based on clinical presentation (imaging, markers)
Age ≥ 18 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 30
Awards & highlights
Study Summary
This trial is evaluating the use of 18F-fluciclovine in women with gynecological cancers.
Eligible Conditions
- Cervical Cancer
- Endometrial Cancer
- Ovarian Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 30
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 30
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
18F-Fluciclovine uptake in gynecologic neoplasms
Trial Design
1Treatment groups
Experimental Treatment
Group I: 18F-FluciclovineExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fluciclovine (18F)
FDA approved
Find a Location
Who is running the clinical trial?
Bital Savir-BaruchLead Sponsor
Blue Earth DiagnosticsIndustry Sponsor
38 Previous Clinical Trials
2,987 Total Patients Enrolled
Bital Savir-Baruch, M.DPrincipal Investigator - Nuclear Medicine Assistant Professor
Gottlieb Memorial Hospital, Loyola University Medical Center
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger